Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia

Leuk Res. 2005 Mar;29(3):253-62. doi: 10.1016/j.leukres.2004.07.012.

Abstract

Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q. Compared to stable disease, more patients with progressive disease had > or =2 anomalies and a high percentage of neoplastic nuclei. Anomalies of genes for basic fibroblast growth factor, interleukin 4, vascular endothelial growth factor or TCL1 were not detected. Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chromosome Aberrations*
  • DNA Probes*
  • Disease Progression
  • Female
  • Fibroblast Growth Factor 2 / genetics
  • Genes, Immunoglobulin
  • Humans
  • Immunoglobulin Variable Region / genetics
  • In Situ Hybridization, Fluorescence
  • Interleukin-4 / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / classification*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / genetics
  • Prognosis
  • Proto-Oncogene Proteins / genetics
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • DNA Probes
  • Immunoglobulin Variable Region
  • Proto-Oncogene Proteins
  • TCL1A protein, human
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • Interleukin-4